QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Research Services
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:QGEN
- CUSIP: N7248210
- Web: www.qiagen.com
- Market Cap: $7.43 billion
- Outstanding Shares: 227,658,000
- 50 Day Moving Avg: $30.24
- 200 Day Moving Avg: $29.31
- 52 Week Range: $20.71 - $32.94
Sales & Book Value:
- Trailing P/E Ratio: 90.14
- Foreward P/E Ratio: 23.65
- P/E Growth: 2.12
- Annual Revenue: $1.35 billion
- Price / Sales: 5.50
- Book Value: $10.67 per share
- Price / Book: 3.06
- EBIDTA: $411.52 million
- Net Margins: 5.85%
- Return on Equity: 10.01%
- Return on Assets: 6.24%
- Debt-to-Equity Ratio: 0.41%
- Current Ratio: 3.36%
- Quick Ratio: 2.92%
- Average Volume: 829,200 shs.
- Beta: 1.05
- Short Ratio: 3.4
Frequently Asked Questions for Qiagen NV (NASDAQ:QGEN)
What is Qiagen NV's stock symbol?
Qiagen NV trades on the NASDAQ under the ticker symbol "QGEN."
How were Qiagen NV's earnings last quarter?
Qiagen NV (NASDAQ:QGEN) announced its earnings results on Wednesday, February, 1st. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.34 by $0.05. The company had revenue of $366.50 million for the quarter, compared to analyst estimates of $372.70 million. Qiagen NV had a return on equity of 10.01% and a net margin of 5.85%. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.31 EPS. View Qiagen NV's Earnings History.
When will Qiagen NV make its next earnings announcement?
What guidance has Qiagen NV issued on next quarter's earnings?
Qiagen NV updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $1.25 - $1.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.24. The company issued revenue guidance of $1.44 billion - $1.47 billion, compared to the consensus revenue estimate of $1.41 billion.Qiagen NV also updated its Q2 guidance to $0.27 - $0.28 EPS.
Where is Qiagen NV's stock going? Where will Qiagen NV's stock price be in 2017?
12 brokerages have issued 12 month price targets for Qiagen NV's shares. Their predictions range from $23.00 to $33.00. On average, they expect Qiagen NV's stock price to reach $28.25 in the next year. View Analyst Ratings for Qiagen NV.
Are investors shorting Qiagen NV?
Qiagen NV saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 2,476,754 shares, a drop of 11.1% from the March 31st total of 2,787,495 shares. Based on an average trading volume of 706,309 shares, the short-interest ratio is currently 3.5 days.
Who are some of Qiagen NV's key competitors?
Some companies that are related to Qiagen NV include Quest Diagnostics (DGX), IDEXX Laboratories (IDXX), Henry Schein (HSIC), Laboratory Corp. of America Holdings (LH), DENTSPLY SIRONA (XRAY), Olympus Corp (OCPNY), GENMAB AS DKK1 (GNMSF), Centene Corp (CNC), Davita (DVA), Hologic (HOLX), Universal Health Services (UHS), Align Technology (ALGN), Lonza Group Ag (LZAGY), Sonova Holding Ag (SONVY), Cooper Companies (COO), H. Lundbeck A/S- (HLUYY), Perrigo Company plc (PRGO) and IPSEN (IPSEY).
Who owns Qiagen NV stock?
Qiagen NV's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (8.08%), BlackRock Inc. (3.47%), Baillie Gifford & Co. (3.20%), Vanguard Group Inc. (2.51%), Manning & Napier Advisors LLC (1.73%) and Johnston Asset Management LLC (1.58%). View Institutional Ownership Trends for Qiagen NV.
Who sold Qiagen NV stock? Who is selling Qiagen NV stock?
Qiagen NV's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Primecap Management Co. CA, Douglas Lane & Associates LLC, Credit Agricole S A, Swiss National Bank, Baillie Gifford & Co., Citadel Advisors LLC and Platinum Investment Management Ltd.. View Insider Buying and Selling for Qiagen NV.
Who bought Qiagen NV stock? Who is buying Qiagen NV stock?
Qiagen NV's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Legal & General Group Plc, Edmond DE Rothschild Holding S.A., Neuberger Berman Group LLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, AQR Capital Management LLC and Credit Suisse AG. View Insider Buying and Selling for Qiagen NV.
How do I buy Qiagen NV stock?
Shares of Qiagen NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Qiagen NV stock cost?
One share of Qiagen NV stock can currently be purchased for approximately $32.64.
Earnings History for Qiagen NV (NASDAQ:QGEN)Earnings History by Quarter for Qiagen NV (NASDAQ:QGEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017|| || || || || || || || |
|2/1/2017||Q416||$0.34||$0.39||$372.70 million||$366.50 million||View||Listen|
|11/2/2016||Q316||$0.28||$0.29||$335.46 million||$338.70 million||View||N/A|
|7/28/2016||Q216||$0.23||$0.24||$326.73 million||$334.40 million||View||N/A|
|4/27/2016||Q116||$0.19||$0.19||$295.76 million||$298.40 million||View||N/A|
|2/2/2016||Q415||$0.32||$0.33||$354.47 million||$349.00 million||View||N/A|
|10/28/2015||Q315||$0.28||$0.27||$323.50 million||$314.60 million||View||Listen|
|7/29/2015||Q215||$0.25||$0.26||$319.43 million||$319.50 million||View||Listen|
|5/7/2015||Q115||$0.22||$0.22||$304.60 million||$298.70 million||View||N/A|
|1/28/2015||Q414||$0.30||$0.25||$367.82 million||$360.80 million||View||N/A|
|10/29/2014||Q3||$0.27||$0.27||$337.00 million||$336.80 million||View||N/A|
|7/29/2014||Q214||$0.25||$0.26||$330.76 million||$331.20 million||View||N/A|
|5/7/2014||Q114||$0.22||$0.22||$317.09 million||$317.40 million||View||N/A|
|1/29/2014||Q413||$0.34||$0.36||$365.52 million||$362.60 million||View||N/A|
|10/29/2013||Q313||$0.25||$0.28||$320.37 million||$323.80 million||View||N/A|
|7/30/2013||Q213||$0.24||$0.27||$311.75 million||$316.40 million||View||N/A|
|4/29/2013||Q113||$0.23||$0.23||$305.50 million||$303.60 million||View||N/A|
|1/29/2013||Q412||$0.31||$0.34||$327.80 million||$346.50 million||View||N/A|
|11/5/2012||Q312||$0.24||$0.26||$303.79 million||$304.30 million||View||N/A|
Earnings Estimates for Qiagen NV (NASDAQ:QGEN)
2017 EPS Consensus Estimate: $1.21
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Qiagen NV (NASDAQ:QGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Qiagen NV (NASDAQ:QGEN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Qiagen NV (NASDAQ:QGEN)
Latest Headlines for Qiagen NV (NASDAQ:QGEN)
Qiagen NV (QGEN) Chart for Wednesday, May, 24, 2017